Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chinyu Su

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Alimentary Pharmacology & Therapeutics|October 11, 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' replyWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Inflammatory Bowel Diseases|August 9, 2020
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical ProgramGary R Lichtenstein, Gerhard Rogler, Matthew A Ciorba, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative ColitisJean-Frederic Colombel, Mark T Osterman, Andrew J Thorpe, et al.
Inflammatory Bowel Diseases|November 7, 2022
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical ProgramGary R Lichtenstein, Brian Bressler, Carlos Francisconi, et al.
Inflammatory Bowel Diseases|June 1, 2022
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibKevin L Winthrop, Séverine Vermeire, Millie D Long, et al.
Inflammatory Bowel Diseases|July 9, 2018
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative ColitisUma Mahadevan, Marla C Dubinsky, Chinyu Su, et al.
Alimentary Pharmacology & Therapeutics|October 6, 2021
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trialsBrian G Feagan, Reena Khanna, William J Sandborn, et al.
Inflammatory Bowel Diseases|December 16, 2020
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial DataJeffrey R Curtis, Miguel Regueiro, Huifeng Yun, et al.
Inflammatory Bowel Diseases|March 20, 2021
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical ProgramBruce E Sands, Millie D Long, Walter Reinisch, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Alimentary Pharmacology & Therapeutics|October 11, 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' replyWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Inflammatory Bowel Diseases|August 9, 2020
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical ProgramGary R Lichtenstein, Gerhard Rogler, Matthew A Ciorba, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative ColitisJean-Frederic Colombel, Mark T Osterman, Andrew J Thorpe, et al.
Inflammatory Bowel Diseases|November 7, 2022
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical ProgramGary R Lichtenstein, Brian Bressler, Carlos Francisconi, et al.
Inflammatory Bowel Diseases|June 1, 2022
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibKevin L Winthrop, Séverine Vermeire, Millie D Long, et al.
Inflammatory Bowel Diseases|July 9, 2018
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative ColitisUma Mahadevan, Marla C Dubinsky, Chinyu Su, et al.
Alimentary Pharmacology & Therapeutics|October 6, 2021
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trialsBrian G Feagan, Reena Khanna, William J Sandborn, et al.
Inflammatory Bowel Diseases|December 16, 2020
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial DataJeffrey R Curtis, Miguel Regueiro, Huifeng Yun, et al.
Inflammatory Bowel Diseases|March 20, 2021
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical ProgramBruce E Sands, Millie D Long, Walter Reinisch, et al.
Pageof 7